New PET tracer could reveal how lung cancer responds to immunotherapy
NCT ID NCT06439914
First seen Jan 08, 2026 · Last updated May 14, 2026 · Updated 23 times
Summary
This early-phase trial is testing a special PET imaging agent that targets a protein called IFN-gamma to see if it can find lung cancer tumors and show how well they respond to immunotherapy. Six adults with untreated non-small cell lung cancer will get a PET scan before starting immunotherapy and again about 30 days after. The goal is to see if this imaging method can help doctors better monitor treatment effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.